vers la météo de la validation par utilisateur
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+-SUBJ:V_PASS-N+COMP:V_PASS-+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,mRNA) COMP:V_PASS-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+-SUBJ:V_PASS-N+COMP:V_PASS-+ | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,mRNA) COMP:V_PASS-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +--------------SUBJ:V_PASS-N--------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ +COMP:V_PASS-+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,expression) COMP:V_PASS-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +--------------SUBJ:V_PASS-N--------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ +COMP:V_PASS-+ | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,expression) COMP:V_PASS-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+-SUBJ:V_PASS-N+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+-SUBJ:V_PASS-N+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+------------------------------------COMP:V-N(by)-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +--------------SUBJ:V_PASS-N--------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,expression)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+------------------------------------COMP:V-N(by)-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +--------------SUBJ:V_PASS-N--------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,expression)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +--------------SUBJ:V_PASS-N--------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ +COMP:V_PASS-+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,expression) COMP:V_PASS-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +--------------SUBJ:V_PASS-N--------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ +COMP:V_PASS-+ | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,expression) COMP:V_PASS-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+------------------------------------COMP:V-N(by)-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+-SUBJ:V_PASS-N+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+------------------------------------COMP:V-N(by)-----------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +--------------SUBJ:V_PASS-N--------------+ | | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,expression)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +---------------------COMP:N-N(by)---------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+-SUBJ:V_PASS-N+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +---------------------COMP:N-N(by)---------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+-SUBJ:V_PASS-N+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +---------------------COMP:N-N(by)---------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+-SUBJ:V_PASS-N+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +---------------------COMP:N-N(by)---------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+-SUBJ:V_PASS-N+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +--------------SUBJ:V_PASS-N--------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ +COMP:V_PASS-+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,expression) COMP:V_PASS-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +--------------SUBJ:V_PASS-N--------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ +COMP:V_PASS-+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,expression) COMP:V_PASS-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+------------------------------------COMP:V-N(by)-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +--------------SUBJ:V_PASS-N--------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,expression)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+------------------------------------COMP:V-N(by)-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +--------------SUBJ:V_PASS-N--------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,expression)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +--------------SUBJ:V_PASS-N--------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ +COMP:V_PASS-+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,expression) COMP:V_PASS-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+------------------------------------COMP:V-N(by)-----------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +--------------SUBJ:V_PASS-N--------------+ | | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,expression)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+-------OBJ:V-N-------+ | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +---SUBJ:V-N---+COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-------OBJ:V-N-------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ +COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+--------COMP:N-N(by)-------+ | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+-SUBJ:V_PASS-N+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) COMP:N-N(by) (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-----------OBJ:V-N-----------+ | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-----------OBJ:V-N-----------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | | +---SUBJ:V-N---+ | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ +COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+-------OBJ:V-N-------+ | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +---SUBJ:V-N---+COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-------OBJ:V-N-------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ +COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+--------COMP:N-N(by)-------+ | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+-SUBJ:V_PASS-N+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) COMP:N-N(by) (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +-----------------OBJ:V-N-----------------+ | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +---SUBJ:V-N---+ | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ +COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-----------OBJ:V-N-----------+ | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-----------OBJ:V-N-----------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | | +---SUBJ:V-N---+ | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ +COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +---SUBJ:V-N---+COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ +COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +-----------------OBJ:V-N-----------------+ | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +---SUBJ:V-N---+ | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ +COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +---------------------COMP:N-N(by)---------------------+ | | +--------------------OBJ:V-N--------------------+ | +--------------SUBJ:V_PASS-N--------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,expression)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +---------------------COMP:N-N(by)---------------------+ | | +--------------------OBJ:V-N--------------------+ | +--------------SUBJ:V_PASS-N--------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,expression)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +---SUBJ:V-N---+COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ +COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+-------OBJ:V-N-------+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-------OBJ:V-N-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-----------OBJ:V-N-----------+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-----------OBJ:V-N-----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | | +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +---------------------COMP:N-N(by)---------------------+ | | +--------------------OBJ:V-N--------------------+ | +--------------SUBJ:V_PASS-N--------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,expression)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +---------------------COMP:N-N(by)---------------------+ | | +--------------------OBJ:V-N--------------------+ | +--------------SUBJ:V_PASS-N--------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,expression)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+-------OBJ:V-N-------+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-------OBJ:V-N-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +-----------------OBJ:V-N-----------------+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-----------OBJ:V-N-----------+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-----------OBJ:V-N-----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | | +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ | | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +-----------------OBJ:V-N-----------------+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ | | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-----------OBJ:V-N-----------+ | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+ +-----------OBJ:V-N-----------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | | +---SUBJ:V-N---+ | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ +COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+--------COMP:N-N(by)-------+ | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+-SUBJ:V_PASS-N+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) COMP:N-N(by) (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+ +-----------OBJ:V-N-----------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | | +---SUBJ:V-N---+ | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ +COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ +COMP:V-N(by)+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA) COMP:V-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ +---------------------COMP:N-N(by)---------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +--------------SUBJ:V_PASS-N--------------+ | | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,expression)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+------------------------------------COMP:V-N(by)-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+-------OBJ:V-N-------+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+------------------------------------COMP:V-N(by)-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+------------------------------------COMP:V-N(by)-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-----------OBJ:V-N-----------+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+------------------------------------COMP:V-N(by)-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+ +-----------OBJ:V-N-----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | | +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+------------------------------------COMP:V-N(by)-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +-----------------OBJ:V-N-----------------+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+-SUBJ:V_PASS-N+ | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ +COMP:V_PASS-+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,mRNA) COMP:V_PASS-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+-SUBJ:V_PASS-N+ | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ +COMP:V_PASS-+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,mRNA) COMP:V_PASS-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+---------------------COMP:N-N(by)---------------------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+-------OBJ:V-N-------+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +---------------------COMP:N-N(by)---------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-------OBJ:V-N-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+---------------------COMP:N-N(by)---------------------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-----------OBJ:V-N-----------+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +---------------------COMP:N-N(by)---------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-----------OBJ:V-N-----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | | +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +--------------SUBJ:V_PASS-N--------------+ | | +--------------------OBJ:V-N--------------------+ | +--------------SUBJ:V-N-------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ | +COMP:V_PASS-+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,expression) SUBJ:V_PASS-N (decrease,expression) COMP:V_PASS-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+---------------------COMP:N-N(by)---------------------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+-------OBJ:V-N-------+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +---------------------COMP:N-N(by)---------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-------OBJ:V-N-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+-SUBJ:V_PASS-N+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+---------------------COMP:N-N(by)---------------------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-----------OBJ:V-N-----------+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +---------------------COMP:N-N(by)---------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-----------OBJ:V-N-----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | | +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +--------------SUBJ:V_PASS-N--------------+ | | +--------------------OBJ:V-N--------------------+ | +--------------SUBJ:V-N-------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ | +COMP:V_PASS-+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,expression) SUBJ:V_PASS-N (decrease,expression) COMP:V_PASS-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +------------------------------------COMP:V-N(by)-----------------------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+-SUBJ:V_PASS-N+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+------------------------------------COMP:V-N(by)-----------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +--------------SUBJ:V_PASS-N--------------+ | | | +--------------------OBJ:V-N--------------------+ | +--------------SUBJ:V-N-------------+ | | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,expression) SUBJ:V_PASS-N (decrease,expression)
+-------------------------------------------COMP:V-N(In)------------------------------------------+------------------------------------COMP:V-N(by)-----------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +--------------SUBJ:V_PASS-N--------------+ | | | +--------------------OBJ:V-N--------------------+ | +--------------SUBJ:V-N-------------+ | | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,expression) SUBJ:V_PASS-N (decrease,expression)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+-SUBJ:V_PASS-N+COMP:V_PASS-+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,mRNA) COMP:V_PASS-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+-SUBJ:V_PASS-N+COMP:V_PASS-+ | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,mRNA) COMP:V_PASS-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +---------------------COMP:N-N(by)---------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+ +-----------OBJ:V-N-----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | | +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +---------------------COMP:N-N(by)---------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+ +-------OBJ:V-N-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +---------------------COMP:N-N(by)---------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+ +-----------OBJ:V-N-----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | | +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ +--------------SUBJ:V_PASS-N--------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +--------------SUBJ:V-N-------------+ | | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ | +COMP:V_PASS-+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,expression) SUBJ:V_PASS-N (decrease,expression) COMP:V_PASS-N(by) (decrease,__NODE__)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+------------------------------------COMP:V-N(by)-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+-SUBJ:V_PASS-N+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+------------------------------------COMP:V-N(by)-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+-SUBJ:V_PASS-N+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,mRNA)
+------------------------------------COMP:V-N(by)-----------------------------------+ +-------------------------------------------COMP:V-N(In)------------------------------------------+ +--------------SUBJ:V_PASS-N--------------+ | | +------------------------------------SUBJ:V-N-----------------------------------+ +--------------SUBJ:V-N-------------+ | | | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,expression) SUBJ:V_PASS-N (decrease,expression)
+------------------------------------COMP:V-N(by)-----------------------------------+ +-------------------------------------------COMP:V-N(In)------------------------------------------+ +--------------SUBJ:V_PASS-N--------------+ | | +------------------------------------SUBJ:V-N-----------------------------------+ +--------------SUBJ:V-N-------------+ | | | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) COMP:V-N(by) (increase,__NODE__) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,expression) SUBJ:V_PASS-N (decrease,expression)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+--------COMP:N-N(by)-------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+-SUBJ:V_PASS-N+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) COMP:N-N(by) (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +---------------------COMP:N-N(by)---------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+-SUBJ:V_PASS-N+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+--------COMP:N-N(by)-------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+-SUBJ:V_PASS-N+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) COMP:N-N(by) (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +---------------------COMP:N-N(by)---------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+-SUBJ:V_PASS-N+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ +---------------------COMP:N-N(by)---------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +--------------SUBJ:V_PASS-N--------------+ | | | +--------------------OBJ:V-N--------------------+ | +--------------SUBJ:V-N-------------+ | | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,expression) SUBJ:V_PASS-N (decrease,expression)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ +---------------------COMP:N-N(by)---------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +--------------SUBJ:V_PASS-N--------------+ | | | +--------------------OBJ:V-N--------------------+ | +--------------SUBJ:V-N-------------+ | | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,expression) SUBJ:V_PASS-N (decrease,expression)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +---------------------COMP:N-N(by)---------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+-SUBJ:V_PASS-N+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+--------COMP:N-N(by)-------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+-SUBJ:V_PASS-N+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) COMP:N-N(by) (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +---------------------COMP:N-N(by)---------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+-SUBJ:V_PASS-N+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) SUBJ:V_PASS-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ +---------------------COMP:N-N(by)---------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +--------------SUBJ:V_PASS-N--------------+ | | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V_PASS-N (decrease,expression)
+---------------------COMP:N-N(by)---------------------+ +-------------------------------------------COMP:V-N(In)------------------------------------------+ +--------------SUBJ:V_PASS-N--------------+ | | +------------------------------------SUBJ:V-N-----------------------------------+ +--------------SUBJ:V-N-------------+ | | | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-MOD_ATT:N-ADJ+ | | | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | | +MOD_AT+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,mRNA) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__SP__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,expression) SUBJ:V_PASS-N (decrease,expression)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-----------COMP:N-N(by)-----------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+-------OBJ:V-N-------+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) COMP:N-N(by) (__NODE__,__NODE__) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +-----------COMP:N-N(by)-----------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-------OBJ:V-N-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) COMP:N-N(by) (__NODE__,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +---------------COMP:N-N(by)---------------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-----------OBJ:V-N-----------+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) COMP:N-N(by) (__SP__,__NODE__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +---------------COMP:N-N(by)---------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-----------OBJ:V-N-----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | | +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) COMP:N-N(by) (__SP__,__NODE__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-----------COMP:N-N(by)-----------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+-------OBJ:V-N-------+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) COMP:N-N(by) (__NODE__,__NODE__) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +-----------COMP:N-N(by)-----------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-------OBJ:V-N-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) COMP:N-N(by) (__NODE__,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +---------------COMP:N-N(by)---------------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-----------OBJ:V-N-----------+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) COMP:N-N(by) (__SP__,__NODE__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +---------------COMP:N-N(by)---------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+ +-----------OBJ:V-N-----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | | +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) COMP:N-N(by) (__SP__,__NODE__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+---------------------COMP:N-N(by)---------------------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +-----------------OBJ:V-N-----------------+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +---------------------COMP:N-N(by)---------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +---------------------COMP:N-N(by)---------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ | | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +---------------------COMP:N-N(by)---------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+---------------------COMP:N-N(by)---------------------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +-----------------OBJ:V-N-----------------+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +---------------------COMP:N-N(by)---------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +---------------------COMP:N-N(by)---------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ | | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ | +---------------------COMP:N-N(by)---------------------+ | | | +-------------COMP:N-N(of)------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) COMP:N-N(of) (nmol/kg/day,day) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +-----------COMP:N-N(by)-----------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+ +-------OBJ:V-N-------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) COMP:N-N(by) (__NODE__,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__NODE__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+ +---------------COMP:N-N(by)---------------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-----------OBJ:V-N-----------+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) COMP:N-N(by) (__SP__,__NODE__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +---------------COMP:N-N(by)---------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+ +-----------OBJ:V-N-----------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | | +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) COMP:N-N(by) (__SP__,__NODE__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+ +---------------COMP:N-N(by)---------------+ +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +-----------OBJ:V-N-----------+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) COMP:N-N(by) (__SP__,__NODE__) MOD_ATT:N-ADJ (mRNA,__NODE__) OBJ:V-N (decrease,__SP__) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +---------------------COMP:N-N(by)---------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ | +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ +COMP:N-N(of+ +MOD_AT+SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__SP__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (mRNA,__NODE__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +---------------------COMP:N-N(by)---------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ +MOD_ATT:N-+ | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) MOD_ATT:N-N (ciglitazone,kidney) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +---------------------COMP:N-N(by)---------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ | | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +---SUBJ:V-N---+ | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
+-------------------------------------------COMP:V-N(In)------------------------------------------+ | +------------------------------------SUBJ:V-N-----------------------------------+ +---------------------COMP:N-N(by)---------------------+ | | +--------------------OBJ:V-N--------------------+ +-----------OBJ:V-N----------+-----------------OBJ:V-N-----------------+ | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(of+ +--COMP:V-N(by)--+ +----COMP:N-N(of)---+ +---SUBJ:V-N---+ | | +MOD_ATT:N-N+ | | +COMP:N+ | +MOD_ATT:+ +MOD+ | +MOD_+ | +MOD_ATT+ +SUBJ:V-N+ | | | | | | | | | | | | | | | | | | | | | | | | In preglomerular artery from __SP__ kidney , ciglitazone ( with a dosage of 9 nmol/kg/day and a treatment period of 21 days ) increases ( by 67 percent ) expression of __SP__ __NODE__ mRNA that is decreased by __NODE__ . MOD_ATT:N-ADJ (__SP__,preglomerular) MOD_ATT:N-N (__SP__,artery) OBJ:V-N (with,nmol/kg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,9) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,day) MOD_ATT:N-ADJ (day,@card@) COMP:V-N(In) (increase,__SP__) SUBJ:V-N (increase,ciglitazone) COMP:V-N(by) (increase,percent) OBJ:V-N (increase,expression) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (expression,__NODE__) COMP:N-N(by) (expression,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) SUBJ:V-N (be,mRNA) OBJ:V-N (decrease,expression) SUBJ:V-N (decrease,mRNA)
